Pharmacist e-Link CE Spotlight
Courses for 5/6/08 - 5/20/08
The Past, Present and Future of Anticoagulation Therapy
This activity will review the past and present of anticoagulation therapy by assessing the role of thrombin in hemostasis, comparing the available therapies and reviewing the current guidelines.
Commercial Support Provided by Boehringer Ingelheim Pharmaceuticals, Inc.
An Update on Diabetes in the Community Pharmacy: Enhancing Patient Compliance through Counseling on Treatment and Delivery Devices
The diagnosis of type 2 diabetes is rapidly growing yet initiation of insulin therapy is often delayed more than eight years from diagnosis greatly increasing the risk of serious complications. Community pharmacists are in an ideal position to introduce patients to products and delivery methods available to enhance outcomes and properly counsel insulin naive patients.
Commercial Support Provided by Pfizer.
Other Featured CE
Thyroid Disease 2007: The Pharmacist, Patient, and Physician Connection
Thyroid dysfunction in the United States is widespread and has significant complications for many of your pharmacy patients. The management of thyroid disease is frequently sub optimal. This program will discuss the ramifications of improper management of thyroid dysfunction and guidelines for the community pharmacist to ensure the best treatment for your patients with thyroid disease.
Commercial Support Provided by Abbott.
The Impact of Diabetes and Associated Cardiometabolic Risk Factors on Members: Strategies for Optimizing Outcomes
This activity will ensure that managed care professionals are informed about new and investigational pharmacotherapeutic agents and technologies in the diabetes and cardiometabolic treatment armamentarium and their impact on the health care landscape.
This activity is supported by an educational grant from Amylin Pharmaceuticals and Eli Lilly and Company.
Improving Chronic Care Management: Connecting Health Information Technology and Quality Measurements
This supplement will explore the factors driving the integration of HIT initiatives in managed care and review the necessary steps in implementing such programs. In particular, MTM programs will be analyzed, as will the use of HIT in the provision of care for chronic disease.
This activity is supported by an educational grant from GlaxoSmithKline
